The role of homozygous CDKN2A/B deletion as an independently prognostic biomarker for worse survival among IDH-wildtype glioblastoma has been indicated [87,88], but the data concerning other genes are very controversial. This evidence concerns the gene CDKN2A and glioblastoma.